Cargando…
A myeloid tumor suppressor role for NOL3
Despite the identification of several oncogenic driver mutations leading to constitutive JAK–STAT activation, the cellular and molecular biology of myeloproliferative neoplasms (MPN) remains incompletely understood. Recent discoveries have identified underlying disease-modifying molecular aberration...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339683/ https://www.ncbi.nlm.nih.gov/pubmed/28232469 http://dx.doi.org/10.1084/jem.20162089 |
_version_ | 1782512705833271296 |
---|---|
author | Stanley, Robert F. Piszczatowski, Richard T. Bartholdy, Boris Mitchell, Kelly McKimpson, Wendy M. Narayanagari, Swathi Walter, Dagmar Todorova, Tihomira I. Hirsch, Cassandra Makishima, Hideki Will, Britta McMahon, Christine Gritsman, Kira Maciejewski, Jaroslaw P. Kitsis, Richard N. Steidl, Ulrich |
author_facet | Stanley, Robert F. Piszczatowski, Richard T. Bartholdy, Boris Mitchell, Kelly McKimpson, Wendy M. Narayanagari, Swathi Walter, Dagmar Todorova, Tihomira I. Hirsch, Cassandra Makishima, Hideki Will, Britta McMahon, Christine Gritsman, Kira Maciejewski, Jaroslaw P. Kitsis, Richard N. Steidl, Ulrich |
author_sort | Stanley, Robert F. |
collection | PubMed |
description | Despite the identification of several oncogenic driver mutations leading to constitutive JAK–STAT activation, the cellular and molecular biology of myeloproliferative neoplasms (MPN) remains incompletely understood. Recent discoveries have identified underlying disease-modifying molecular aberrations contributing to disease initiation and progression. Here, we report that deletion of Nol3 (Nucleolar protein 3) in mice leads to an MPN resembling primary myelofibrosis (PMF). Nol3(−/−) MPN mice harbor an expanded Thy1(+)LSK stem cell population exhibiting increased cell cycling and a myelomonocytic differentiation bias. Molecularly, this phenotype is mediated by Nol3(−/−)-induced JAK–STAT activation and downstream activation of cyclin-dependent kinase 6 (Cdk6) and Myc. Nol3(−/−) MPN Thy1(+)LSK cells share significant molecular similarities with primary CD34(+) cells from PMF patients. NOL3 levels are decreased in CD34(+) cells from PMF patients, and the NOL3 locus is deleted in a subset of patients with myeloid malignancies. Our results reveal a novel genetic PMF-like mouse model and identify a tumor suppressor role for NOL3 in the pathogenesis of myeloid malignancies. |
format | Online Article Text |
id | pubmed-5339683 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53396832017-09-06 A myeloid tumor suppressor role for NOL3 Stanley, Robert F. Piszczatowski, Richard T. Bartholdy, Boris Mitchell, Kelly McKimpson, Wendy M. Narayanagari, Swathi Walter, Dagmar Todorova, Tihomira I. Hirsch, Cassandra Makishima, Hideki Will, Britta McMahon, Christine Gritsman, Kira Maciejewski, Jaroslaw P. Kitsis, Richard N. Steidl, Ulrich J Exp Med Research Articles Despite the identification of several oncogenic driver mutations leading to constitutive JAK–STAT activation, the cellular and molecular biology of myeloproliferative neoplasms (MPN) remains incompletely understood. Recent discoveries have identified underlying disease-modifying molecular aberrations contributing to disease initiation and progression. Here, we report that deletion of Nol3 (Nucleolar protein 3) in mice leads to an MPN resembling primary myelofibrosis (PMF). Nol3(−/−) MPN mice harbor an expanded Thy1(+)LSK stem cell population exhibiting increased cell cycling and a myelomonocytic differentiation bias. Molecularly, this phenotype is mediated by Nol3(−/−)-induced JAK–STAT activation and downstream activation of cyclin-dependent kinase 6 (Cdk6) and Myc. Nol3(−/−) MPN Thy1(+)LSK cells share significant molecular similarities with primary CD34(+) cells from PMF patients. NOL3 levels are decreased in CD34(+) cells from PMF patients, and the NOL3 locus is deleted in a subset of patients with myeloid malignancies. Our results reveal a novel genetic PMF-like mouse model and identify a tumor suppressor role for NOL3 in the pathogenesis of myeloid malignancies. The Rockefeller University Press 2017-03-06 /pmc/articles/PMC5339683/ /pubmed/28232469 http://dx.doi.org/10.1084/jem.20162089 Text en © 2017 Stanley et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Research Articles Stanley, Robert F. Piszczatowski, Richard T. Bartholdy, Boris Mitchell, Kelly McKimpson, Wendy M. Narayanagari, Swathi Walter, Dagmar Todorova, Tihomira I. Hirsch, Cassandra Makishima, Hideki Will, Britta McMahon, Christine Gritsman, Kira Maciejewski, Jaroslaw P. Kitsis, Richard N. Steidl, Ulrich A myeloid tumor suppressor role for NOL3 |
title | A myeloid tumor suppressor role for NOL3 |
title_full | A myeloid tumor suppressor role for NOL3 |
title_fullStr | A myeloid tumor suppressor role for NOL3 |
title_full_unstemmed | A myeloid tumor suppressor role for NOL3 |
title_short | A myeloid tumor suppressor role for NOL3 |
title_sort | myeloid tumor suppressor role for nol3 |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339683/ https://www.ncbi.nlm.nih.gov/pubmed/28232469 http://dx.doi.org/10.1084/jem.20162089 |
work_keys_str_mv | AT stanleyrobertf amyeloidtumorsuppressorrolefornol3 AT piszczatowskirichardt amyeloidtumorsuppressorrolefornol3 AT bartholdyboris amyeloidtumorsuppressorrolefornol3 AT mitchellkelly amyeloidtumorsuppressorrolefornol3 AT mckimpsonwendym amyeloidtumorsuppressorrolefornol3 AT narayanagariswathi amyeloidtumorsuppressorrolefornol3 AT walterdagmar amyeloidtumorsuppressorrolefornol3 AT todorovatihomirai amyeloidtumorsuppressorrolefornol3 AT hirschcassandra amyeloidtumorsuppressorrolefornol3 AT makishimahideki amyeloidtumorsuppressorrolefornol3 AT willbritta amyeloidtumorsuppressorrolefornol3 AT mcmahonchristine amyeloidtumorsuppressorrolefornol3 AT gritsmankira amyeloidtumorsuppressorrolefornol3 AT maciejewskijaroslawp amyeloidtumorsuppressorrolefornol3 AT kitsisrichardn amyeloidtumorsuppressorrolefornol3 AT steidlulrich amyeloidtumorsuppressorrolefornol3 AT stanleyrobertf myeloidtumorsuppressorrolefornol3 AT piszczatowskirichardt myeloidtumorsuppressorrolefornol3 AT bartholdyboris myeloidtumorsuppressorrolefornol3 AT mitchellkelly myeloidtumorsuppressorrolefornol3 AT mckimpsonwendym myeloidtumorsuppressorrolefornol3 AT narayanagariswathi myeloidtumorsuppressorrolefornol3 AT walterdagmar myeloidtumorsuppressorrolefornol3 AT todorovatihomirai myeloidtumorsuppressorrolefornol3 AT hirschcassandra myeloidtumorsuppressorrolefornol3 AT makishimahideki myeloidtumorsuppressorrolefornol3 AT willbritta myeloidtumorsuppressorrolefornol3 AT mcmahonchristine myeloidtumorsuppressorrolefornol3 AT gritsmankira myeloidtumorsuppressorrolefornol3 AT maciejewskijaroslawp myeloidtumorsuppressorrolefornol3 AT kitsisrichardn myeloidtumorsuppressorrolefornol3 AT steidlulrich myeloidtumorsuppressorrolefornol3 |